A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin [bevacizumab] as Frontline Therapy for Metastatic Breast Cancer

Trial Profile

A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin [bevacizumab] as Frontline Therapy for Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2017 Status changed from discontinued to completed.
    • 27 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Jun 2010 New source identified and integrated (Barbara Ann Karmanos Cancer Institute, 2007-050).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top